Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol (Q34434723)

2 August 2017

Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol (English)

1 reference

2 August 2017

1 reference

7

Komajda M

1 reference

2 August 2017

Home PD

1

1 reference

2 August 2017

Pocock SJ

2

1 reference

2 August 2017

Beck-Nielsen H

3

1 reference

2 August 2017

Gomis R

4

1 reference

2 August 2017

Hanefeld M

5

1 reference

2 August 2017

Dargie H

6

1 reference

2 August 2017

Gubb J

8

1 reference

2 August 2017

Biswas N

9

1 reference

2 August 2017

Jones NP

10

1 reference

2 August 2017

16 July 2005

1 reference

2 August 2017

1 reference

2 August 2017

48

1 reference

2 August 2017

1726-1735

1 reference

2 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s00125-005-1869-1

2 August 2017

0 references

cites work

Effect of thiazolidinediones on high-density lipoprotein subfractions

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-005-1869-1

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-005-1869-1

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

12 December 2020

A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

1 reference

12 December 2020

A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones

1 reference

12 December 2020

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

1 reference

12 December 2020

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

12 December 2020

Prospective analysis of the insulin-resistance syndrome (syndrome X).

1 reference

12 December 2020

Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone

1 reference

12 December 2020

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

12 December 2020

Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes

1 reference

12 December 2020

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure

1 reference

12 December 2020

A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999

1 reference

12 December 2020

Development of a Type 2 Diabetes Symptom Checklist: a Measure of Symptom Severity

1 reference

12 December 2020

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

12 December 2020

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

12 December 2020

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

1 reference

12 December 2020

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

1 reference

12 December 2020

Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study

1 reference

12 December 2020

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

1 reference

12 December 2020

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

1 reference

12 December 2020

Hepatotoxicity with thiazolidinediones: is it a class effect?

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

1 reference

12 December 2020

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

12 December 2020

10.1007/S00125-005-1869-1

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference